Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Gene For Deadly Inherited Lung Disease Identified By Scientists
A rare, deadly developmental disorder of the lungs called alveolar capillary dysplasia with misalignment of pulmonary veins (ACD/MPV) that usually kills the infants born with it within the first month of life results from deletions or mutations in the FOXF1 transcription factor gene, said a consortium of researchers led by Baylor College of Medicine (www.bcm.edu) in a report that appears in the American Journal of Human Genetics.

Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks
An innovative treatment for infections of the respiratory tract in cystic fibrosis patients has received a second orphan drug designation in the US only weeks after a first designation was granted. The recent designation relates to Burkholderia cepacia pathogens that can cause lethal infections in cystic fibrosis patients. For Axentis Pharma AG of Zurich, Switzerland, both designations affirm the therapeutic potential of its product candidate Fluidosomes(TM)-tobramycin, whose unique microbiological profile sets it apart from other antibiotic formulations (including free tobramycin).
News of the day
UNICEF: Children And Women Displaced By Conflict In Pakistan Need Urgent And Ongoing Support
UNICEF is deeply concerned about the condition of thousands of children who have been displaced by conflict, or who remain in affected areas, in north-western Pakistan. Nearly 50 per cent of the estimated 2 million displaced are children, many of whom are in urgent need of health and educational services, nutritional support, access to clean water and sanitation as well as protection. Their situation has been compounded by the harsh summer temperatures.
Cardiovascular

New Clinical Study On Type 2 Diabetes Begins Enrollment At New York Hospital Queens

Diabetes affects nearly 24 million people in the United States. The most widespread form is type 2 diabetes, accounting for about 90 to 95 percent of all diagnosed cases of diabetes, according to the American Diabetes Association (ADA). The research team at New York Hospital Queens is offering the community a chance to participate in a new type 2 diabetes study. The study, called TINSAL-T2D (Targeting Inflammation using Salsalate in Type 2 Diabetes), looks at the safety and effectiveness of an investigational medication (similar to aspirin) in the treatment of type 2 diabetes. The study medication has been approved by the U.S. Food and Drug Administration to treat arthritis, but it has not yet been approved for diabetes. To be eligible for this study, participants must have type 2 diabetes, be between 18 and 75 years old, and be on a stable dose of oral anti-diabetic medication and the diabetes is still not well controlled. The study includes 12 visits to the Lang Research Center over approximately one year. Qualified participants will receive a physical exam and laboratory tests at no cost. Participants will be compensated for their time and effort. Nationally lauded endocrinologist, Daniel Lorber, M.D., associate director, Eugene and Theresa Lang Research Center for Research and Education at New York Hospital Queens, is the principal investigator of the clinical trial. Last month, Dr. Lorber received the ADA"s "Outstanding Physician Clinician Award" for his contributions to the ongoing fight against diabetes. A clinical trial is a scientific study that evaluates the safety and effectiveness of medical treatments, drugs or devices. These studies are required by the U.S. Food and Drug Administration for manufacturers to earn approval for new products and new uses for existing products. New York Hospital Queens is a member of the NewYork-Presbyterian Healthcare System and is an affiliate of the Weill Medical College of Cornell University. American Diabetes Association


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009